-

Medable to Present at Jefferies Global Healthcare Conference

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., the leading evidence-generation platform provider for modern clinical trials, today announced that Medable Co-founder and CEO Michelle Longmire will present at the Jefferies Global Healthcare Conference. The live presentation will take place on Thursday, June 6, 2024, at 3:30p.m. ET in New York City, New York.

The Management Team will also be available for 1:1 investor meetings at the conference. Please reach out to your Jefferies representative to schedule.

For more information, please contact:
Burak Over
SVP, Corporate Development & Investor Relations
burak@medable.com

To learn more about Medable, visit medable.com.

About Medable

Medable is on a mission to get effective therapies to people faster. Its digital clinical trials platform enhances speed, scale, and patient access in clinical research, accelerating medicines for thousands of conditions without treatment or cure. Named a Leader in the industry by Everest Group and awarded Best Digital Health Solution by the Galien Foundation, the Medable platform has been deployed in more than 300 trials in 60 countries and 120 languages, serving more than one million patients globally. Medable is a privately held, venture-backed company headquartered in Palo Alto, California, and ranked #398 on the Inc. 5000 in 2023.

Contacts

Lisa Barbadora, Barbadora INK for Medable
+1 (610) 420-3413
lbarbadora@barbadoraink.com / media@medable.com

Medable Inc.

Details
Headquarters: Palo Alto, California
CEO: Michelle Longmire
Employees: 350
Organization: PRI

Release Versions

Contacts

Lisa Barbadora, Barbadora INK for Medable
+1 (610) 420-3413
lbarbadora@barbadoraink.com / media@medable.com

Social Media Profiles
More News From Medable Inc.

MRCT Center and Medable Launch New Resources for Investigator Oversight in Decentralized Clinical Trials

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., a leading provider of agentic clinical development technology, and the Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard (MRCT Center) today announced new resources for sponsors and investigators. The tools will be available beginning September 23, 2026. The resources and practical tools help sponsors and investigators determine which trial activities can appropriately take place closer to participants and establi...

Medable and ICON Exceed Patient eConsent Adoption Goals for Women’s Health Study on Menopause

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., the leading technology platform for agentic AI clinical development, today announced the impact of its Total Consent solution in a U.S women’s health study on menopause managed by ICON plc. Beating expectations, more than 85% of trial participants, or 1,044 out of 1,222, consented using Medable’s enhanced eConsent technology. And, 18 sites achieved 100% eConsent adoption among participants, while the top-enrolling site achieved 91% adoption. With...

New Tufts CSDD Analysis Finds AI Agents Can Deliver Up to $21 Million in Net Financial Value Per Drug Development Program and Up to 82x ROI

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., the leading technology platform for agentic clinical development, today announced a new Tufts Center for the Study of Drug Development (CSDD) analysis showing that an AI clinical monitoring agent can deliver net financial gains as high as $21 million per drug development program and 82 times the return on investment. The findings are based on benchmarked oncology program and clinical trial data from Tufts CSDD and contract value and experience d...
Back to Newsroom